The phase III FLAURA trial (First-Line-AURA; NCT02296125) in EGFR-mutated treatment-naïve NSCLC patients was designed to compare osimertinib 80 mg daily vs. the current standard of care gefitinib or erlotinib. Here, EGFR is linked to non-small cell lung carcinoma.